Development of a complementary PET/MR dual-modal imaging probe for targeting prostate-specific membrane antigen (PSMA).

We tried to develop a dual-modal PET/MR imaging probe using a straightforward one-pot method by encapsulation with specific amphiphiles. In this study, iron oxide (IO) nanoparticles were encapsulated with three amphiphiles containing PEG, DOTA and the prostate-specific membrane antigen (PSMA)-targeting ligand in aqueous medium.

The diameter of the prepared nanoparticle DOTA-IO-GUL was 11. 01 ± 1. 54 nm. DOTA-IO-GUL was labeled with (68)Ga in high efficiency. The DOTA-IO-GUL showed a dose-dependent binding to LNCaP (PSMA positive) cells via a competitive binding study against (125)I-labeled MIP-1072 (PSMA-targeting agent). Additionally, PET and MR imaging results showed PSMA selective uptake by only 22Rv1 (PSMA positive) but not PC-3 (PSMA negative) in dual-tumor xenograft mouse model study. MR imaging showed high resolution, and PET imaging enabled quantification and confirmation of the specificity. In conclusion, we have successfully developed the specific PSMA-targeting IO nanoparticle, DOTA-IO-GUL, as a dual-modality probe for complementary PET/MR imaging.

Nanomedicine : nanotechnology, biology, and medicine. 2015 Dec 28 [Epub ahead of print]

Sung-Hyun Moon, Bo Yeun Yang, Young Ju Kim, Mee Kyung Hong, Yun-Sang Lee, Dong Soo Lee, June-Key Chung, Jae Min Jeong

Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea; Department of Radiation Applied Life Science, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea; Department of Radiation Applied Life Science, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea; Department of Radiation Applied Life Science, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.  

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe